Brief: An2 Therapeutics Provides Update On Epetraborole Ex-U.S. Development Plan In Treatment-Refractory Mac Lung Disease
06/10/2022 12:04
Oct 6 (Reuters) - AN2 Therapeutics Inc ANTX.O :
* AN2 THERAPEUTICS PROVIDES UPDATE ON EPETRABOROLE EX-U.S.
DEVELOPMENT PLAN IN TREATMENT-REFRACTORY MAC LUNG DISEASE
* AN2 THERAPEUTICS PROVIDES UPDATE ON EPETRABOROLE EX-U.S.
DEVELOPMENT PLAN IN TREATMENT-REFRACTORY MAC LUNG DISEASE
* AN2 THERAPEUTICS INC - EPETRABOROLE GRANTED ORPHAN
MEDICINAL
PRODUCT DESIGNATION IN NTM LUNG DISEASE IN EUROPEAN UNION
Source text for Eikon: ID:nGNX6rLlgr
Further company coverage: ANTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview